Company Leadership

Executive Management

Simon Williams, Ph.D., President, CEO & Director

Dr. Williams has been the President and a Director of Tepha since its formation. He is a cofounder of Metabolix, Tepha’s sister company, and served on the Metabolix Board of Directors since its formation in 1992 until 2006. Dr. Williams led the spinout of Tepha from Metabolix. Prior to co-founding Metabolix, Dr. Williams was a lecturer in organic chemistry at Manchester University in England, and a visiting scientist and NATO postdoctoral fellow at M.I.T. He completed a Ph.D. in organic chemistry at Cambridge University, England.

John Hartnett, Executive Vice President, & COO

Mr. Hartnett has over 20 years of experience in medical devices, and was formerly the Director of Business Development at Boston Scientific. His experiences range from product sales, product marketing, business development, and strategic planning for a variety of medical device product ranges. He holds an M.B.A. from Boston University.

Said Rizk, Sr. Vice President of Manufacturing and Process Technologies

Mr. Rizk is a leading expert in the development of processes to produce new medical fibers and devices, and joined Tepha in 2003. He has over 20 years of experience in the medical device industry. He developed and commercialized numerous products at Ethicon, Inc., a division of Johnson and Johnson. At U.S. Surgical, Inc., Mr. Rizk was Sr. Director of Engineering; and in this capacity he helped make U.S. Surgical into a suture company.

Mary P. LeGraw, Vice President of Regulatory Affairs

Ms. LeGraw joined Tepha in 2004, and has over 18 years of medical device regulatory affairs experience. She was previously Vice President of Regulatory Affairs for OmniSonics, a developer of technology using acoustic energy for the treatment of vascular occlusive disease. Prior to that appointment, she held positions in regulatory affairs at Mitek, a J&J company, with a focus on sports medicine, and at Boston Scientific where she managed programs on peripheral interventional radiology, interventional neuroradiology, and cardiovascular devices.

Robert Brennan, Senior Director of Quality Systems

Mr. Brennan has 20 years of experience with quality systems, and joined Tepha in 2004. He was formerly Director of Quality for Genzyme Biosurgery, supporting cardiothoracic, fluid management, wound closure, and biomaterial product lines. Prior to his appointment at Genzyme, he held positions at Johnson & Johnson, as well as at C.R. Bard’s Davol Division, the leading manufacturer of hernia meshes.

David Martin, Ph.D., Senior Director of Research & Development

Dr. Martin is an expert on the development of medical applications with the Company’s PHA biomaterials and their manufacture, and has been with Tepha since its inception. He has over 12 years of R&D experience with the Company’s biomaterials, and previously worked at Metabolix on various aspects of PHA biochemistry, synthesis, and applications development. He completed a Ph.D. in organic chemistry at Stanford University in 1994.

Board of Directors

Richard Emmitt, Director

Mr. Emmitt is a Managing Director of The Vertical Group, a New Jersey-based medical device venture capital partnership that succeeded the venture capital activities of F. Eberstadt & Co. Mr. Emmitt has been recognized as one of the leading experts on the healthcare industry, with more than thirty years’ experience in healthcare-related venture capital, investment research, and investment banking. He currently serves on the board of several public and private medical device companies, including American Medical Systems, BioSet, ENTrigue Surgical, ev3, and Tornier. Mr. Emmitt was also involved in the successful development of SciMed Life Systems and Xomed Surgical Products, which were ultimately acquired by Boston Scientific and Medtronic, respectively. He holds an M.B.A from The Rutgers School of Business.

Edward Giles, Director

Mr. Giles is a Special Limited Partner of The Vertical Fund, and Chairman of The Vertical Group. From 1979 through 1985, he was President of F. Eberstadt & Co., and then Vice Chairman of Eberstadt Fleming until 1988. Mr. Giles received a B.Ch.E. from Princeton University in 1957 and a S.M. (industrial management) from the Massachusetts Institute of Technology in 1959. He is also a board member of Ventana Medical Systems and Metabolix, Inc.

Edward Muller, Director

Mr. Muller is the former Chairman of Metabolix, and also served as President of that company from 1993 to 1999. Prior to Metabolix, Mr. Muller served Halcon International in a number of functions, both technical and financial, ultimately assuming CEO responsibilities. Halcon was responsible for the development of several key processes used in the production of raw materials for the polyester, nylon, polystyrene, and polyurethane industries. Mr. Muller was active in technology evaluation, financing and planning, and structuring ventures to use these technologies. He received a B.Ch.E. from The Cooper Union in 1959 and a M.B.A. (finance and economics) from New York University in 1968.

Anthony Sinskey, Sc.D., Director

Dr. Sinskey is Professor of Microbiology in the Department of Biology at the Massachusetts Institute of Technology. He is a well-recognized expert on transgenic methods for producing Tepha’s biomaterials, and is a joint inventor of the Company’s transgenic production technology. He is also a cofounder and board member of Metabolix. Dr. Sinskey earned a Sc.D. from M.I.T. in 1966.